Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor presented as a solution for injection for subcutaneous use. It stimulates neutrophil production and is used to treat neutropenia associated with chemotherapy and other hematologic conditions.

GNH USA supplies Neupogen as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) is a granulocyte colony‑stimulating factor used to manage neutropenia and related hematologic disorders. - Chemotherapy‑induced neutropenia: reduces the duration of neutropenia and lowers infection risk in patients receiving cytotoxic chemotherapy. - Aplastic anemia: supports neutrophil recovery in patients with bone‑marrow failure. - Bone marrow transplantation: promotes engraftment by stimulating neutrophil precursor proliferation. - Congenital neutropenia: increases neutrophil counts in patients with inherited neutrophil production defects.

Filgrastim may cause a range of adverse reactions, most of which are related to its pharmacologic activity on the bone marrow and immune system.

Common Side Effects: - Bone pain: discomfort in the limbs or back, often mild to moderate. - Injection site reactions: redness, swelling, or itching at the subcutaneous site. - Fever: transient elevation of body temperature. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Splenic rupture: rare but potentially life‑threatening abdominal emergency. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Allergic reactions: anaphylaxis, urticaria, or angioedema. - Leukocytosis: excessively high white blood cell counts.

When prescribing or handling Neupogen, several safety considerations should be observed. - Monitor blood counts: regularly assess neutrophil levels to adjust therapy. - Assess infection risk: evaluate for active infections before initiating treatment. - Use caution in splenomegaly: patients with enlarged spleen may have higher rupture risk. - Adjust for renal impairment: consider dose modification in severe kidney dysfunction. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with obstetric specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Chemotherapy agents: concurrent use may alter neutrophil recovery; coordinate timing. - Corticosteroids: high‑dose steroids can blunt the neutrophil response to filgrastim.

Moderate Interactions (Monitor Closely): - Antimicrobial agents: may mask signs of infection; monitor clinical status. - Immunosuppressants: increased risk of infection; observe closely. - Vaccines (live): reduced vaccine efficacy; consider timing of administration.